- Gene structure information identified by combining Compugen's
AI/ML predictive computational discovery platform,
Unigen™ with Ultima's UG 100™ sequencing platform to
better understand tumor biology and immune regulation
- Leveraging Compugen's computational analytical tools uncovered
high consistency in single-cell expression levels across Ultima's
UG 100 sequencing platform, offering a potential advantage for
demarcation of transcript termination.
- Research presented at Advances in Genome Biology and Technology
(AGBT) 2025 General Meeting
HOLON, Israel, Feb. 26,
2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq:
CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company
and a pioneer in computational target discovery,
today announced results generated in a joint research
collaboration, combining Compugen's AI/ML powered predictive
computational discovery platform, Unigen, with high throughput
single cell sequencing on Ultima's UG 100 to uncover new insights
on gene structure for immuno-oncology.
"We are excited to collaborate with Ultima Genomics, a pioneer
in next generation gene sequencing, to enhance our proprietary gene
sequencing database, which is part of our Unigen platform," said
Eran Ophir, Ph.D., Chief Scientific
Officer at Compugen. "We developed algorithms to study gene
splicing in single cell resolution and applied it to analyze
patient tumor samples to uncover new potential regulatory
mechanisms in immuno-oncology. Some of the findings were presented
at the AGBT conference. Compugen plans to further harness Ultima's
technology to develop its proprietary single cell atlases for
accelerated discovery of new immunotherapies."
"We are excited to support Compugen's capabilities in predictive
computational discovery of new drug targets and development of new
cancer immunotherapies," said Gilad Almogy, Founder and CEO of
Ultima Genomics. "We built our innovative sequencing architecture
and our UG 100 sequencing platform to enable researchers to
unlock new applications and insights through lower cost sequencing
and more omics data. The successful outcome of our collaboration
with Compugen is a great example of an application that is
data-starved due to the constraints of conventional sequencing
technology and can be transformed through large scale data and
AI/ML techniques. Single cell sequencing is also an excellent fit
for our technology which is now compatible with the leading library
prep technologies."
Dr. Roy Granit, Head of
Computational Discovery at Compugen is the lead author on a poster
presented by Ultima Genomics at the Advances in Genome Biology and
Technology (AGBT) 2025 general meeting on February 25, 2025, in Marco Island, Florida.
Poster presentation details:
Title: Using 3' Single Cell Sequencing to Study
Patient-Derived Tumor Cells Reveals Enhanced Potential to Study
Differential Splicing at the Cell Type Level
Poster number: 224
Date and time: Tuesday, February
25, 4:45 p.m. - 6:10 p.m.
ET
Leading author: Roy Granit,
Ph.D., Director, Head of Computational Discovery, Compugen,
Israel
Presenter: Zohar Shipony, Ph.D. Ultima Genomics,
United States
Key Findings:
- Comparative analysis using tumor samples from cancer patients,
found high consistency in single-cell expression levels across
Ultima Genomics' UG 100 and Illumina's Novaseq 6000 sequencing
platforms.
- UG 100 offers clearer demarcation of 3' mRNA transcript end and
provides a unique opportunity to study gene structure, which can
potentially be harnessed to better understand tumor biology and
immune regulation.
- Gene structure information identified in this approach is
contributing to the predictive models of Unigen.
The poster is available on the publications section of
Compugen's website, www.cgen.com.
About Unigen™
Compugen has been at the forefront of decoding cancer biology,
with its AI/ML powered predictive computational discovery platform,
recently branded as Unigen™. Unigen is Compugen's code-to-cure,
flexible-loop platform for the computational prediction of novel
drug target discovery and development of cancer immunotherapy.
Unigen combines Compugen's deep scientific knowledge, AI/ML
predictive algorithms and a cloud-based, technology-agnostic
platform integrating a variety of biological data such as
multi-omics, single-cell RNA sequencing and spatial omics data. The
outcomes from Compugen's preclinical and clinical trials enrich the
proprietary knowledgebase to discover additional novel drug targets
and further understand complex biology. To date, Unigen has yielded
multiple novel immuno-oncology drug targets, potential first- or
best-in-class clinical stage immuno-oncology programs, validating
partnerships with multiple pharmaceutical companies and undisclosed
programs in its early-stage pipeline.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery platform (Unigen™) to identify new drug
targets and biological pathways for developing cancer
immunotherapies. Compugen has two proprietary product candidates in
Phase 1 development: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a
PD-1/TIGIT bispecific antibody where the TIGIT component is derived
from Compugen's clinical stage anti-TIGIT antibody, COM902, is in
Phase 3 development by AstraZeneca through a license agreement for
the development of bispecific and multispecific
antibodies. GS-0321 (previously COM503), a potential
first-in-class, high affinity anti-IL-18 binding protein antibody,
which is in Phase 1 development is licensed to Gilead. In addition,
the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance.
Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended, and the safe-harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on the current beliefs,
expectations, and assumptions of Compugen. Forward-looking
statements can be identified using terminology such as "will,"
"may," "expects," "anticipates," "believes," "potential," "plan,"
"goal," "estimate," "likely," "should," "confident," and "intends,"
and similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking
statements include, but are not limited to, statement regarding
Ultima's UG 100™ sequencing platform offering a potential
advantage for demarcation of transcript termination and statements
regarding Compugen's plans to further harness Ultima's technology
to develop its proprietary single cell atlases for accelerated
discovery of new immunotherapies. These forward-looking statements
involve known and unknown risks and uncertainties that may cause
the actual results, performance, or achievements of Compugen to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Among these risks: the clinical trials of any product
candidates that Compugen, or any current or future collaborators,
may develop may fail to satisfactorily demonstrate safety and
efficacy to the FDA, and Compugen, or any collaborators, may incur
additional costs or experience delays in completing, or ultimately
be unable to complete, the development and commercialization of
these product candidates; Compugen's business model is
substantially dependent on entering into collaboration agreements
with third parties and Compugen may not be successful in generating
adequate revenues or commercializing aspects of its business model;
Compugen's approach to the discovery of therapeutic products is
based on its proprietary computational target discovery
infrastructure, which is unproven clinically; general market,
political and economic conditions in the countries in which
Compugen operates, including Israel; the effect of the evolving nature of
the recent war in Gaza; and
Compugen does not know whether it will be able to discover and
develop additional potential product candidates or products of
commercial value. These risks and other risks are more fully
discussed in the "Risk Factors" section of Compugen's most recent
Annual Report on Form 20-F as filed with the Securities and
Exchange Commission (SEC) as well as other documents that may be
subsequently filed by Compugen from time to time with the SEC. In
addition, any forward-looking statements represent Compugen's views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
Compugen contact:
Yvonne
Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-enhances-its-aiml-predictive-computational-discovery-platform-unigen-with-ultima-genomics-single-cell-genomics-sequencing-technology-302385891.html
SOURCE Compugen Ltd.
